The art of allocation

The alternatives unit at Credit Suisse is one of the largest and most sophisticated fund-of-hedge-funds managers in the world. Ramon Koss (right), head of alternative investments, talks to Navroz Patel about his unit’s unique approach to investment and risk management

0804-creditsuisse-gif

Unlike some of its main competitors, financial services firm Credit Suisse stays extremely tight-lipped about the size of its alternative investments business. According to one ultra-high-net-worth individual that was pitched to by the Swiss house last year, it had, at that point, around $30 billion worth of assets under management in alternative strategies.

The analysts Risk spoke to all put it among the top five largest allocators to hedge funds, with a consensus that it is probably

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Chartis RiskTech100® 2024

The latest iteration of the Chartis RiskTech100®, a comprehensive independent study of the world’s major players in risk and compliance technology, is acknowledged as the go-to for clear, accurate analysis of the risk technology marketplace. With its…

T+1: complacency before the storm?

This paper, created by WatersTechnology in association with Gresham Technologies, outlines what the move to T+1 (next-day settlement) of broker/dealer-executed trades in the US and Canadian markets means for buy-side and sell-side firms

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here